Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children

Pediatric Dermatology

Volumn 25, Issue 1, 2008, Pages 88-95

  Myhre, Paula E ^a   Levy, Moise L ^b   Eichenfield, Lawrence F ^c   Kolb, Vicki B ^a   Fielder, Sandra L ^a,d   Meng, Tze Chiang ^a  

^a 3M COMPANY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMIQUIMOD; MOMETASONE FUROATE;

APPLICATION SITE PAIN; AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DRUG BLOOD LEVEL; DRUG SAFETY; ECZEMA; EDEMA; ERYTHEMA; FEMALE; HUMAN; LYMPHADENOPATHY; MALE; MOLLUSCUM CONTAGIOSUM; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHARYNGITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN ULCER; STOMATITIS; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGE FACTORS; AMINOQUINOLINES; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON INDUCERS; MALE; MAXIMUM TOLERATED DOSE; MOLLUSCUM CONTAGIOSUM; PROBABILITY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 39849111177     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2007.00590.x     Document Type: Article

References (17)

1. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002 3 : 196 200.
2. Gibson SJ, Imbertson LM, Wagner TL et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 1995 15 : 537 545.
3. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002 27 : 571 577.
4. Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papilloma Virus. Arch Dermatol 1998 134 : 25 30.
5. Geisse J, Caro I, Lindholm J et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004 50 : 722 733.
6. Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004 50 : 714 721.
7. Moresi JM, Herbert CT, Cohen BA. Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream. Pediatr Dermatol 2001 18 : 448 450.
8. Grussendorf-Conen EI, Jacobs S, Rubben A et al. Topical 5% imiquimod long-term treatment of cutaneous warts resistant to standard therapy modalities. Dermatology 2002 205 : 139 145.
9. Welsh O, Olazaran Z, Gomez M et al. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 2004 51 : 639 642.
10. Theos AU, Cummins R, Silverberg NB et al. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis 2004 74 : 134 138, 141 142.
11. Harrison LI, Skinner SL, Marbury TC et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004 296 : 6 11.
12. Lund CC, Browder NC. The estimation of area of burns. Surg Gynecol Obstet 1944 79 : 352 358.
13. Gunzer M, Riemann H, Basoglu Y et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 2005 106 : 2424 2432.
14. Gil J, Rullas J, Alcami J et al. MC159L protein from the poxvirus molluscum contagiosum virus inhibits NF-κB activation and apoptosis induced by PKR. J Gen Virol 2001 82 : 3027 3034.
15. Xiang Y, Moss B. IL-18 binding and inhibition of interferon γ induction by human poxvirus-encoded proteins. Proc Natl Acad Sci U S A 1999 96 : 11537 11542.
16. Nichols DB, Shisler JL. The MC160 protein expressed by the dermatotropic poxvirus molluscum contagiosum virus prevents tumor necrosis factor alpha-induced NF-kappaB activation via inhibition of I kappa kinase complex formation. J Virol 2006 80 : 578 586.
17. Gibson SJ, Lindh JM, Riter TR et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002 218 : 74 86.